MicroStrategy devotee Semler Scientific doubles down on Bitcoin buy – Mara Holdings (NASDAQ: MARA)

Semler Scientific Inc SMLRa medical technology company, announced its entry into the cryptocurrency space with its latest convertible note offering and plans for acquisitions Bitcoin BTC/USD.
what happened: On Jan. 24, Semler Scientific priced $85 million in 4.25% convertible senior notes due in 2030, according to the company’s press release.
The offering was initially set at $75 million, which was increased due to strong investor interest.
The notes will convert into shares of Semler common stock at an initial conversion price of approximately $76.44 per share, which is 25% higher than the last reported sale price of the stock.
Notably, Semler Scientific intends to use a portion of the net proceeds “for general corporate purposes, including the acquisition of Bitcoin,” marking a significant shift in the company’s treasury management strategy.
The move puts Semler in line with other publicly traded companies that have adopted Bitcoin as a treasury asset, such as microscience Mstr.
Also Read: Here’s What Donald Trump’s ‘Crypto Czar’ Will Do Now
Why it matters: The company’s decision to invest in Bitcoin comes within a broader trend of corporate Bitcoin adoption.
Bitcoin miners, e.g. Marathon Digital Holdings Mara increasingly adopted “BTC Yield” Strategyinspired by MicroStrategy’s aggressive approach to Bitcoin accumulation.
In Asia, Metaplanet Inc. Also making waves with its Bitcoin investment strategy. The publicly traded company recently purchased $10.4 million worth of Bitcoin, bringing its total holdings to more than 1,018 BTC, worth approximately $67.1 million.
Metaplanet’s approach mirrors that of MicroStrategy, which positions itself as “Asia’s answer to micro”.
To date, Micronography itself has accumulated 461,000 Bitcoins.
Semler Scientific last made headlines in December 2024 when it expanded its Bitcoin holdings to over $180 million.
Read next:
Image: shutterstock
This content is produced in part with the help of AI tools, and has been reviewed and published by Benzinga editors.
Market news and data brought to you by Benzinga API
©2025 benzinga.com. Benzinga does not provide investment advice. all rights reserved.